Loading...
Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019?
The use of rituximab for the treatment of immune thrombocytopenia was greeted enthusiastically: it led to up to 60% response rates, making it, nearly 20 years ago, the main alternative to splenectomy, with far fewer side effects. However, long-term follow-up data showed that only 20-30% of patients...
Na minha lista:
| Udgivet i: | Haematologica |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Ferrata Storti Foundation
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6545833/ https://ncbi.nlm.nih.gov/pubmed/31126963 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2019.218883 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|